Tricida Inc

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

LOS ANGELES--(BUSINESS WIRE)--SierraConstellation Partners (“SCP”), a national interim management and advisory firm, has been awarded top industry accolades for the firm's work on the restructuring of Tricida, Inc. (“Tricida”), a clinical-stage pharmaceutical company focused on the development and commercialization of a drug for the treatment of chronic kidney disease. SCP was awarded: The M&A Advisor Turnaround Award for Healthcare/Life Sciences Deal of the Year (Over $100MM) The M&A A.

SierraConstellation Partners Receives Industry Recognition for Work with Tricida

Wilmington, Delaware--(Newsfile Corp. - February 8, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Tricida, Inc. (NASDAQ: TCDA) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-tricida-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tricida, Inc.

Cutera

Baxter

Third Harmonic Bio Inc

Vera Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

5 Cheapest Health Care Stocks You Should Think About - Baxter Intl (NYSE:BAX), Cutera (NASDAQ:CUTR)

Tricida Inc., a clinical-stage pharmaceutical company working on a kidney disease drug, has filed for Chapter 11 bankruptcy protection in Delaware, with roughly US$350 million of debt, according to a court filing. The San Francisco-based company will try to sell itself out of bankruptcy and has signed a restructuring support agreement (RSA) with 80% of its convertible noteholders, according to court papers.

Tricida files for Chapter 11 bankruptcy protection as it searches for a buyer

Akebia Therapeutics

The Beachbody Co.

ComSovereign Holding

Faraday Future Intelligent Electric

Nymox Pharmaceutical

Rigel Pharmaceuticals

Sonim Technologies Inc

Statera Biopharma Inc

Titan Medical Inc

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1 This Week

Allogene Therapeutics Inc

AST SpaceMobile

Bed Bath & Beyond

Beyond Meat

Carvana

Mullen Automotive

PMV Pharmaceuticals

Upstart Holdings

Vertex Energy

The difficult state of the macroeconomic environment in 2022 has had a negative impact on the performance of a number of equity investments. Worries about a recession and a bearish attitude among investors have been especially unsettling for companies with weak financial positions.

Top 10 most-shorted stocks as of November 2022

Helbiz

Hycroft Mining Holding Corporation

Kalera PLC

 Nuwellis

OneConnect Financial Tech Co Ltd ADR

Polished.com Inc

Stryve Foods

Penny stocks to buy for under $1 but are they worth the risk? The post 10 Top Penny Stocks To Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1 Right Now

Canoo

Opendoor

These industries could be worth looking into to find penny stocks to watch The post What Penny Stocks Industries Are Popular Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What Penny Stocks Industries Are Popular Right Now?

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives.

Tricida Announces Third Quarter 2022 Financial Results

Camber Energy

Imperial Petroleum

Trading under $1 penny stocks? Use these tips The post What to Look For in Penny Stocks Under $1, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Look For in Penny Stocks Under $1, 3 Tips

Fangdd Network Group

Meta Materials

Check these tips out for trading penny stocks right now The post Buying Cheap Penny Stocks in November? 3 Tips to Use  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Buying Cheap Penny Stocks in November? 3 Tips to Use

Nokia

Are these the reasons you're not profiting with penny stocks? The post Top Reasons You're Not Making Money With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Reasons You're Not Making Money With Penny Stocks

Tricida Provides Strategic Update

The stock price of Tricida (TCDA) plummeted 94.48% in the most recent trading session. This is why.

Tricida (TCDA) Stock: Why It Plummeted 94.48%

Tricida (NASDAQ: TCDA ) stock is falling on Monday following the release of poor results from a Phase 3 clinical trial. That trial covers the use of veverimer to treat patients suffering from metabolic acidosis and chronic kidney disease (CKD).

Why Is Tricida (TCDA) Stock Down 90% Today?

Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

Hercules Capital

Tricida Announces $125 Million Debt Facility with Hercules Capital

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Tricida, Inc. (“Tricida” or the “Company”) (NASDAQ: TCDA) on behalf of the Company's long-term investors.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) announced today that a late-breaking clinical trial abstract on the Phase 3, VALOR-CKD renal outcomes trial has been selected by the American Society of Nephrology (ASN) and the Kidney Week Education Committee for oral presentation in the High-Impact Clinical Trials session at the ASN Kidney Week 2022 meeting that is currently scheduled to take place November 3 to 6, 2022 in Orlando, Florida. The presentation entitled “V

Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Tricida, Inc. (NasdaqGS: TCDA). On July 15, 2020, the Company disclosed that it received a notification from the U.S. Food and Drug Administration (FDA) regarding its ongoing review of the Company's New Drug Application (NDA) for its drug candidate, veverimer (TRC101) wherein “the FDA

TRICIDA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

TCDA has a major binary event next month. Data from VALOR may turn out well given the logic behind early trial termination, prior data and so on.

Tricida: Important Binary Event Coming Up

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company's key initiatives. The presentation will be accessible on the Tricida website at IR.Tricida.com on Monday, September 12, 2022 at 4:30 pm PT / 1:30 pm ET. An archive of the presentation will be available for 90 days following the presenta

Tricida to Present at the H.C. Wainwright 24th Annual Global Investment Conference

TRICIDA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

Tricida, Inc. (NASDAQ:TCDA ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jackie Cossmon - VP of IR & Communications Gerrit Klaerner - Founder, President, CEO & Executive Director Geoffrey Parker - COO, CFO & EVP Conference Call Participants Eva Privitera - Cowen and Company Serge Belanger - Needham & Company Jessica Fye - JPMorgan Chase & Co. Operator Ladies and gentlemen, thank you for standing by, and welcome to the Tricida Second Quarter 2022 Financial Results Conference Call. [Operator Instructions].

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q2 2022 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida Announces Second Quarter 2022 Financial Results

Tricida Announces Second Quarter 2022 Financial Results

News for Tricida Inc Stock (TCDA)